Board of Directors
Introduction
The Board of Sonova Holding AG is responsible for the overall strategic direction and supervising the management of the company (see Art. 716a para. 1 of the Swiss Code of Obligations). Its working methods are reflected in the Organizational Regulations and the Board Committee Charters (available for the Audit Committee, the Nomination and Compensation Committee, and the Technology and Innovation Committee).
Board of Directors independence
Board members are considered to be independent, according to Section 15 of the Swiss Code of Best Practice for Corporate Governance and Art. 6 para. 3 of the Organizational Regulations, if they personally or in association with related persons have not been a Group Executive during the last three years, have not served as lead auditor of the external auditor during the last two years, and have no or only comparatively minor business relations with the company. According to these rules, all Board members are considered to be independent.
Board of Directors fees
The compensation of the Board members is structured in a manner that supports their independence. Board members therefore receive fixed compensation only, consisting of a cash retainer and non-discounted shares subject to a blocking period of three years from the grant date. The share component strengthens alignment with shareholdersʼ interests. In addition, Board members receive fixed committee retainers for their service on the Board committees. Board members do not receive any performance-related compensation, severance payments, or additional benefits. Further details are provided in the relevant chapters of the Compensation Report.
Executive management positions
No Board member holds an executive management position with Sonova Holding AG or any of its subsidiaries or has held such a position in the past three years.
Business connections of members of the Board of Directors with Sonova Holding AG or its subsidiaries
In the 2025/26 financial year, no business relationships existed between individual Board members, including companies or organizations represented by them, and Sonova Holding AG or its subsidiaries.
Other activities and vested interests
Except as disclosed in the biographies of the Board members, no such member holds a position in a governing or supervisory body of any significant private or public sector organization, institution, or foundation. Furthermore, no Board member holds any permanent executive or consulting position with a significant interest group, nor any public or political office.
Mandates outside Sonova Holding AG
No Board member may hold more than four mandates in listed companies and no more than five mandates in other companies and organizations. Mandates shall mean mandates in comparable functions at other enterprises as well as in (trading) associations, organizations, foundations, and similar legal entities with an economic purpose.
The following mandates are not subject to these limitations:
- Mandates in companies that are controlled by Sonova or that control Sonova; and
- Mandates held at the request of Sonova or companies controlled by Sonova, provided no Board member holds more than ten such mandates.
For further details see Art. 30 of the Articles of Association, and the Compensation Report for outside mandates to be disclosed under the Swiss Code of Obligations.
Board of Directors competence and evaluation
The Nomination and Compensation Committee and the Board assess both current and prospective Board members against a structured competency and experience framework encompassing skills, experience and culture. The framework is built on core personal attributes – including an entrepreneurial mindset, a collaborative and learning-oriented approach, the ability to, perform and transform, and a strong performance orientation – and covers key areas of expertise such as executive and board experience, strategy and transformation, technology and innovation, digitalization and data analytics, consumer and retail, MedTech and B2B, global experience, capital markets, mergers and acquisitions, and governance and oversight. The Board is also committed to fostering diversity and inclusion across gender, age, nationality, ethnicity, and cultural background.
Based on this framework, the Nomination and Compensation Committee and the Board regularly review the composition of the Board to identify potential capability gaps and to define candidate profiles for future appointments. As a result of this process, the Board will propose three new members for election at the Annual General Meeting 2026: Ingrid Cotoros, Malina Man Lin Ngai, and Hooi Ling Tan. At the same time, Lynn Dorsey Bleil and Ronald van der Vis will not stand for re-election at this AGM. Subject to the election of all three proposed candidates, the number of Board members will increase from eight to nine for the upcoming term of office.
In addition, the Board conducts an annual self-assessment with the objective to:
- Ensure and deepen its comprehensive understanding of the business and the Company;
- Evaluate the performance of the Board, its committees, the individual Board members, and the Board Chair;
- Make optimal use of the collective skills and experience represented on the Board; and
- Improve the efficiency and effectiveness of working methods, and cooperation between the Board and Group Executive Management.
The Board Chair oversees the annual self-assessment process by distributing an approved evaluation questionnaire, consolidating the results, and presenting the findings to the Nomination and Compensation Committee and the full Board for discussion.
Composition of the Board of Directors
As of 31 March 2026, the composition of the Board is as follows:
Gilbert Achermann | Gregory Behar | Lynn Dorsey Bleil | Roland Diggelmann | Laura Stoltenberg | Julie Tay | Ronald van der Vis | Adrian Widmer | |||||||||
Age | 61 | 56 | 62 | 58 | 52 | 59 | 58 | 57 | ||||||||
Tenure (years) | 2 | 5 | 10 | 5 | 1 | 4 | 17 | 6 | ||||||||
Gender | ||||||||||||||||
Female | x | x | x | |||||||||||||
Male | x | x | x | x | x | |||||||||||
Committee Member | ||||||||||||||||
Audit | x | x | x | |||||||||||||
Nomination & Compensation | x | x | x | |||||||||||||
Technology and Innovation | x | x | x | x | ||||||||||||
Independent | x | x | x | x | x | x | x | x |
Election, term of office, and biographies
Election procedure and limits on the term of office
Art. 16 para. 1 of the Articles of Association of Sonova Holding AG states that the Board must consist of a minimum of five and a maximum of ten members. Board members are elected by the shareholders at the Annual General Meeting (Art. 10 no. 2 of the Articles of Association).
Re-election for successive terms is permitted. Board members are required to retire automatically at the first Annual General Meeting following their seventieth birthday. In justified individual cases, the Board may grant an exemption. Further details are set out in Art. 6 of the Organizational Regulations.
First election and remaining term of office
The following table sets out the date of first election for each Board member. Under the Articles of Association, the term of office of a Board member expires with the completion of the next Annual General Meeting. Accordingly, Board members are subject to re-election each year at the Annual General Meeting. At the 2025 Annual General Meeting all proposed Board members were re-elected, with the exception of Laura Stoltenberg, who was elected to the Board for the first time at that meeting.
Name | Position | First elected | ||
Gilbert Achermann | Chair | 2024 | ||
Gregory Behar | Member | 2021 | ||
Lynn Dorsey Bleil | Member | 2016 | ||
Roland Diggelmann | Member | 2021 | ||
Laura Stoltenberg | Member | 2025 | ||
Julie Tay | Member | 2022 | ||
Ronald van der Vis | Member | 2009 | ||
Adrian Widmer | Member | 2020 |
Gilbert Achermann

(Born 1964, Swiss citizen) has served as Chair of the Board of Directors of Sonova Holding AG since June 2025. He has been a non‑executive member of the Board since 2024 and is Chair of the Technology and Innovation Committee.
Gilbert Achermann served as Chair of the Board of Directors of Straumann Group from 2010 to 2024. Prior to this, he held the roles of Chief Financial Officer and subsequently Chief Executive Officer at Straumann Group, where he spent more than 12 years and played a key role in the companyʼs development into a global leader in the dental industry. In 2020, he was elected to the Board of Directors of Ypsomed Group and became its Chair in 2022. In the same year, he joined the Board of Directors of Unilabs S.A. and was appointed Chair of the Board in 2023.
Since 2019, Gilbert Achermann has been a member of the Foundation Board and Supervisory Board of IMD in Lausanne, Switzerland, and was elected Vice Chair in 2026. He has also been a member of the Management Board of Swiss Medtech since 2020 and has served as its Vice President since 2024. From 2012 to 2024, he was a member of the Board of Directors of Julius Baer Group.
Gilbert Achermann holds a degree in Business Administration from the University of Applied Sciences in St. Gallen and completed the Executive MBA program at IMD in Lausanne, Switzerland.
Outside mandates
Listed companies:
- Board Chair of Ypsomed Group
Other mandates:
- Board Chair of Unilabs S.A.
- Board member of Greenteg AG (note: Gilbert Achermann will not stand for re-election at Greenteg AGʼs AGM in June 2026)
- Member of the Management Board and Vice President of the Swiss Medtech Association
- Foundation Board and Supervisory Board of IMD – International Institute for Management Development in Lausanne
Gregory Behar

(Born 1969, Swiss citizen) has served as a non‑executive member of the Board of Directors of Sonova Holding AG since 2021. He is a member of the Nomination and Compensation Committee and member of the Technology and Innovation Committee.
Since January 2024, Gregory Behar has been Chief Executive Officer of Recipharm AB, a contract development and manufacturing organization (CDMO) in the pharmaceutical industry. Prior to this, he served as Chief Executive Officer of Nestlé Health Science from 2014 until 31 December 2023 and became a member of the Nestlé Executive Board in 2017. From 2011 to 2014, he was President and Chief Executive Officer of Boehringer Ingelheim Pharmaceuticals Inc. (USA).
Earlier in his career, he held various leadership positions at Boehringer Ingelheim GmbH (Germany), Novartis AG and Nestlé SA.
Gregory Behar holds an MBA from INSEAD, France, a Master of Science in Mechanical Engineering and Manufacturing from EPFL Lausanne, Switzerland, and a Bachelor of Science in Mechanical Engineering from the University of California, Los Angeles, USA
Outside mandates
Listed companies:
- n.a.
Other mandates:
- CEO of Recipharm AB
- Board member of Amazentis SA
- Board member of New Biologix (mandate held at the direction of Recipharm AB in his capacity as its CEO and not considered an additional outside mandate)
Lynn Dorsey Bleil

(Born 1963, US citizen) has served as a non‑executive member of the Board of Directors of Sonova Holding AG since 2016. She is a member of the Technology and Innovation Committee and the Audit Committee.
Lynn Dorsey Bleil retired as Senior Partner (Director) from McKinsey & Company in the United States in 2013, after more than 25 years advising senior management teams and boards of healthcare companies. Her work focused on corporate and business unit strategy, mergers and acquisitions, and public policy across the healthcare value chain. She has served on the boards of Auspex Pharmaceuticals until its acquisition by Teva in March 2015, of DST Systems until its acquisition by SS&C in April 2018, and of Stericycle Inc. until its acquisition by Waste Management in November 2024.
Lynn Dorsey Bleil holds a Bachelorʼs degree in Chemical Engineering from Princeton University, USA, and a Master of Business Administration from the Stanford University Graduate School of Business, USA.
Lynn Dorsey Bleil will not stand for re‑election at the 2026 Annual General Meeting.
Outside mandates
Listed companies:
- Board member of Alcon Inc.
- Board member of Amicus Therapeutics Inc.
Other mandates:
- Chair of the Intermountain Healthcare Wasatch Back Hospitals Community Board (non-profit organization)
Roland Diggelmann

(Born 1967, Swiss citizen) has served as a non‑executive member of the Board of Directors of Sonova Holding AG since 2021. He is a member and Chair of the Nomination and Compensation Committee.
From 2019 until 31 March 2022, Roland Diggelmann served as Chief Executive Officer of Smith & Nephew plc, a UK‑based global medical technology company active in orthopaedics, sports medicine and advanced wound management. Prior to this, he was Managing Director for the Asia Pacific region of Roche Diagnostics from 2008 to 2012. In 2012, he was appointed Chief Executive Officer of Roche Diagnostics, a role he held until 2018. During this period, he led Rocheʼs global diagnostics business and was a member of the Roche Corporate Executive Committee.
Earlier in his career, he held senior management positions in sales and marketing as well as strategic planning at Zimmer Holdings and Sulzer Medica (later Centerpulse). Roland Diggelmann has more than 25 years of international executive experience in the medical technology and life sciences sector, including Chief Executive Officer roles in global organizations.
He studied Business Administration at the University of Bern, Switzerland.
Outside mandates
Listed companies:
- Board Chair of Mettler Toledo International Inc.
Other mandates:
- Board member of Berlin Heals AG
- Board member of HeartForce AG
- Board member of Navignostics AG
- Board member of Osler Diagnostics Ltd.
Laura Stoltenberg

(Born 1973, US citizen) has served as a non‑executive member of the Board of Directors of Sonova Holding AG since 2025. She is a member of the Technology and Innovation Committee.
Laura Stoltenberg currently serves as President and Chief Executive Officer of Cryosa, a clinical‑stage medical device company developing a novel therapeutic solution for obstructive sleep apnea.
Prior to her current role, she held various senior leadership positions at Halma plc, Medtronic and GE Healthcare, with responsibilities spanning global operations, business development and technology‑driven healthcare solutions. She brings extensive executive experience in the medical technology sector, including leadership in growth initiatives, mergers and acquisitions, and business development, as well as in operational improvement and cost management within regulated healthcare environments.
Laura Stoltenberg holds a Master of Business Administration from Columbia Business School, USA, and Bachelorʼs degrees in Electrical Engineering and Management from Bucknell University, USA.
Outside mandates
Listed companies:
- n.a.
Other mandates:
- President and CEO of Cryosa
Julie Tay

(Born 1966, Singapore citizen) has served as a non‑executive member of the Board of Directors of Sonova Holding AG since 2022. She is a member of the Nomination and Compensation Committee.
From 2013 to 2022, Julie Tay served as Senior Vice President and Managing Director, Asia Pacific, at Align Technology, Inc., and was a member of the companyʼs global Executive Management Committee. Align Technology is a global medical device company specializing in digital orthodontics and restorative dentistry, including the Invisalign system, iTero intraoral scanners and exocad CAD/CAM software. In this role, she was responsible for the Asia Pacific region, overseeing commercial operations, market development and organizational leadership across multiple markets.
Prior to Align Technology, Julie Tay held various management positions at Bayer Healthcare, JohnsonDiversey and Johnson & Johnson Medical, with responsibilities across commercial, operational and regional leadership functions.
Julie Tay holds a Bachelor of Arts degree from the National University of Singapore and a Master of Business Administration in International Marketing from Curtin University of Technology, Australia.
Outside mandates
Listed companies:
- Board member of EBOS Group Ltd.
Other mandates:
- n.a.
Ronald van der Vis

(Born 1967, Dutch citizen) has served as a non‑executive member of the Board of Directors of Sonova Holding AG since 2009. He is a member of the Audit Committee and chaired the committee from 2019 to 2021.
From 2009 until November 2012, Ronald van der Vis served as Group Chief Executive Officer of Esprit Holdings Limited, a global fashion and lifestyle company listed on the Hong Kong Stock Exchange. He previously held senior management roles at GrandVision N.V. (formerly Pearle Europe), which he joined in 1998, and served as Group Chief Executive Officer from 2004 to 2009.
His experience includes executive leadership roles in consumer‑facing and retail businesses, as well as involvement in mergers and acquisitions and corporate finance through executive and private‑equity operating roles.
He graduated from Nyenrode Business University in the Netherlands and holds a Masterʼs degree in Business Administration from Alliance Manchester Business School, United Kingdom.
Ronald van der Vis will not stand for re‑election at the 2026 Annual General Meeting.
Outside mandates
Listed companies:
- n.a.
Other mandates:
- Operating Partner, Co-Investor and Industry Advisor
- Supervisory Board Chair of European Dental Group
- Supervisory Board Chair of Equipe Zorgbedrijven
- Supervisory Board member of HEMA BV
Adrian Widmer

(Born 1968, Swiss citizen) has served as a non‑executive member of the Board of Directors of Sonova Holding AG since 2020. He is a member and Chair of the Audit Committee.
Since 2014, Adrian Widmer has served as Group Chief Financial Officer of Sika AG, a global specialty chemicals company headquartered in Switzerland. In this role, he is responsible for the Groupʼs finance, controlling and reporting functions. Prior to this, he was Head of Group Controlling and Mergers & Acquisitions at Sika from 2007 to 2014.
Before joining Sika, he held various management positions at BASF, Degussa and Textron Inc., with responsibilities across finance and controlling, business development and general management. Adrian Widmer has more than 25 years of executive experience in finance, controlling, business development, and M&A including long‑standing service as Group Chief Financial Officer of a listed industrial company.
He holds a Master of Science degree in Business and Economics from the University of Zurich, Switzerland, and has completed the Advanced Management Program at INSEAD, Fontainebleau, France.
Outside mandates
Listed companies:
- Group CFO of Sika AG
Other mandates:
- n.a.
Internal organizational structure
Allocation of tasks within the Board of Directors
As specified in Art. 17 para. 1 of the Articles of Association, the Board constitutes itself, except for the Board Chair and the members of the Nomination and Compensation Committee, who must be elected by the shareholders. If the office of the Board Chair or a member of the Nomination and Compensation Committee is vacant, pursuant to Art. 16 para. 4 of the Articles of Association, the Board appoints a replacement from among its members for the remaining term of office. The duties of the Board Chair are set out in Art. 21 of the Organizational Regulations, and the duties of the Vice-Chair are set out in Art. 23 of the Organizational Regulations.
In accordance with Art. 19 para. 1 of the Organizational Regulations, which supplements the Articles of Association, the Board appoints an Audit Committee.
Tasks and areas of responsibility of Board of Directorsʼ committees
The duties and authorities of the committees are defined in the Articles of Association, the Organizational Regulations, and the Board Committee Charters (available for the Audit Committee, the Nomination and Compensation Committee, and the Technology and Innovation Committee).
The committees usually meet before the meetings of the Board, report regularly on activities and make proposals to the Board based on their findings. The overall responsibility for duties delegated to the committees remains with the Board.
Audit Committee
The members of the Audit Committee are Adrian Widmer (AC Chair), Lynn Dorsey Bleil, and Ronald van der Vis.
The duties of the Audit Committee include reviewing the performance and effectiveness of external and internal audits on behalf of the entire Board; evaluating the companyʼs financial control systems, financial structure, and risk management control mechanisms; and verifying the interim and annual accounts and financial statements of the Sonova Group. The Audit Committee is also kept regularly informed on the companyʼs compliance program. Further details can be found in the Audit Committee Charter.
The Audit Committee meets as often as required but no fewer than four times per financial year. During the reporting period, the Audit Committee met four times. The Board Chair was invited to, and attended, every Audit Committee meeting as a guest.
Nomination and Compensation Committee
The members of the Nomination and Compensation Committee are Roland Diggelmann (NCC Chair), Gregory Behar, and Julie Tay.
The Nomination and Compensation Committee supports the mission of the Board to attract, retain, and motivate people with outstanding professional and personal capabilities on Board and top management levels. In the selection and nomination processes, the committee considers independence, expertise, experience, and skills (including those related to economic, environmental, and social aspects) needed for the respective corporate bodyʼs tasks, seeking where possible to establish balance in diversity terms including but not limited to: gender, age, nationalities or country of origin, ethnicity, competencies, experiences, ways of believing, and mindsets. The Nomination and Compensation Committee also supports the Board in preparing the Compensation Report, establishing and reviewing the companyʼs compensation principles, guidelines, and performance metrics, and preparing proposals to the General Shareholdersʼ Meeting on the compensation of the Board and Group Executives. The committee may also submit proposals and recommendations to the Board on other compensation-related issues. Further details can be found in the Nomination and Compensation Committee Charter.
The Nomination and Compensation Committee meets as often as required but no fewer than four times per financial year. During the reporting period, the committee met five times and held two additional conference calls on relevant subject matters. The Board Chair was invited to, and attended, every Nomination and Compensation Committee meeting as a guest.
Technology and Innovation Committee
The members of the newly implemented Technology and Innovation Committee are Gilbert Achermann (TIC Chair), Gregory Behar, Lynn Dorsey Bleil, and Laura Stoltenberg.
The Technology and Innovation Committee guides and oversees the companyʼs technology, innovation and AI strategies, ensuring Sonova stays ahead of technological developments and evolving consumer needs. The committee represents an expansion of the Boardʼs engagement and governance, strengthening the Boardʼs insights, oversight and deeper expertise, while improving its ability to define and drive Sonovaʼs technology, innovation, and solutions roadmap.
The Committee meets at least twice per financial year, with Sonovaʼs CEO attending as a standing guest. External members may be appointed at the discretion of the TIC Chair. During the reporting period, the committee met once on relevant subject matters.
Working methods of the Board of Directors and its committees
During the reporting period, the Board held five regular meetings and four additional conference calls on relevant subject matters. The table below shows the individual membersʼ attendance at Board and committee meetings, as well as the average length of the meetings:
BoD meetings | 1) | BoD add. Calls | 2) | AC meetings | 3) | NCC meetings | 4) | NCC add. Calls | 5) | TIC meetings | 6) | |||||||
No. of meetings in 2025/26 | 5 | 4 | 4 | 5 | 2 | 1 | ||||||||||||
Gilbert Achermann | 5 | 4 | 4 | 7) | 5 | 7) | 2 | 7) | 1 | |||||||||
Gregory Behar | 5 | 4 | 1 | 4 | 2 | 1 | ||||||||||||
Lynn Dorsey Bleil | 5 | 3 | 4 | 1 | ||||||||||||||
Roland Diggelmann | 5 | 4 | 5 | 2 | ||||||||||||||
Laura Stoltenberg | 5 | 2 | 1 | |||||||||||||||
Julie Tay | 5 | 4 | 5 | 2 | ||||||||||||||
Ronald van der Vis | 5 | 4 | 4 | |||||||||||||||
Adrian Widmer | 5 | 4 | 4 | |||||||||||||||
Average meeting length | 8.5h | 1.5h | 3h | 3h | 1.5h | 4 |
1)Regular Board meetings in person.
2)Additional calls of the Board.
3)Regular meetings of the Audit Committee (AC) in person.
4)Regular meetings of the Nomination and Compensation Committee (NCC) in person.
5)Additional calls of the Nomination and Compensation Committee (NCC).
6)Regular meetings of the Technology and Innovation Committee (TIC) in person.
7)As a guest.
Urgent business matters were discussed at various telephone conferences. In addition to formal meetings at which minutes were taken, Board members or the committees also frequently met informally for other topics and discussions that required additional time. These included, but were not limited to, preparations for formal meetings, interviews, nomination of key individuals, and reviewing M&A projects.
The agenda for a meeting of the Board and its committees is determined by the respective Chair. Any Board member or a committee may request a meeting be convened or an item be included on the agenda. Board members and the committee members receive all relevant documents sufficiently in advance of meetings to enable adequate preparation for discussions on agenda items. The Board and its committees constitute a quorum when at least half of their respective members are present. Resolutions are adopted by a majority of the members present. In the event of a tie, the Chair has the casting vote.
The Board works closely with the Group Executives. As a general rule, meetings of the Board and its committees are attended by the CEO, the CFO and, depending on the agenda, other members of the Group Executives or key employees. Following each meeting, the Board and respective committees hold an executive session. Where appropriate, the Board engages external experts to support the execution of specific tasks.
During the 2025/26 financial year, the five regular meetings of the Board were attended by the CEO and other Group Executives to review, amongst other topics, performance against plan, key initiatives, and strategic matters. If necessary, the Board also consults with other internal experts (such as the Group General Counsel & Chief Compliance Officer) or external advisors.
All four meetings of the Audit Committee were attended by the Board Chair as a guest. The CEO, the CFO, and the Head of Internal Audit & Risk participated in all four meetings of the Audit Committee. Representatives of the auditors participated in two out of these four meetings.
All five meetings of the Nomination and Compensation Committee were attended by the Board Chair as a guest and were held in the presence of the CEO and the Group Vice President Corporate Human Resources and Communications.
The meeting of the Technology and Innovation Committee was chaired by the Board Chair, and attended by Board members, the CEO, the CFO, Group Executives, and other members of the companyʼs top management.
Definition of areas of responsibility
The Board of Sonova Holding AG is responsible for the overall strategic direction of the company, except in matters reserved by law to the Annual General Meeting. The Board decides on all matters that have not been reserved for or conferred upon another governing body of the company by law, by the Articles of Association, or by the Organizational Regulations. The delineation of responsibility between the Board and the Group Executives is set out in detail in the Organizational Regulations.
Information and control instruments vis-à-vis Group Executives
The Group Executives report regularly to the Board and its committees. At each Board meeting, the executive management provides updates on current business matters, financial results, and strategic initiatives, including major transactions such as mergers and acquisitions. Once a year, a dedicated Board meeting is held to discuss the companyʼs strategy and long-term financial planning. The Board receives comprehensive monthly financial reports and the CEOʼs performance report. In addition, conference calls between Board members and the CEO or CFO are held as required. Each member of the Board is entitled to request information on all company relating matters.
Internal audit, risk, and compliance
The mandates, reporting lines and scope of Internal Audit and Risk Management, are defined in the Internal Audit & Risk Charter, which is approved by the Audit Committee and the Board. Internal Audit performs compliance and operational audits, and provides independent assurance on the effectiveness of the internal control environment. The Group Executives are responsible for managing business risks and ensuring compliance with applicable laws and regulations. The Audit Committee approves the annual audit and risk work plans, reviews completed audit reports, and monitors the implementation of corrective actions. The Head of Internal Audit & Risk reports directly to the Chair of the Audit Committee.
The Group has established a comprehensive risk management system to identify, assess and manage strategic, operational, financial, legal, cyber, and compliance risks. Risk management proposals are prepared by the Group Executives, reviewed by the Audit Committee, and approved by the Board. Risks are assessed based on their severity and likelihood, and the overall approach is aligned with recognized international standards, including the COSO framework. Risk Management also oversees the Internal Control System (ICS) for financial reporting, with the Board receiving annual compliance updates. Sonovaʼs Group compliance program supports the companyʼs values of ethical behavior and integrity. It is administered by the Head Group Compliance and overseen by the Group General Counsel & Chief Compliance Officer. Key elements of the program include operation of the ethics hotline, maintenance of the policy framework, employee training, and due-diligence processes for business partners. Quarterly compliance reports are submitted to the Audit Committee and a comprehensive annual report is provided to the Board.
Sustainability
Sonovaʼs Sustainability Strategy is an integral part of its overall business strategy. Improvement indicators are embedded across the organization, and ambitious sustainability targets are set alongside financial objectives.
Sonova has established an ESG Council, which oversees and further develops the Groupʼs Sustainability strategy, monitors key performance indicators, and meets at least quarterly. The ESG Council is attended by the CEO, selected Group Executives, the Group General Counsel & Chief Compliance Officer, and Corporate Sustainability team. The Board approves the Sustainability strategy, initiatives, and targets, and regularly receives progress updates from the Group Executives – further details are provided in the Sustainability Report.
Key Sustainability topics for Sonova include climate change, access to hearing care, product quality, talent management, data privacy, and digital ethics. Sonovaʼs Tax Principles define the procedures and internal guidelines governing tax compliance across the Group. Sonova also maintains an active dialogue on sustainability-related topics with proxy advisors, investors, and rating agencies. As part of its broader governance and reporting framework, the CEO and Corporate Human Resource Management prepare an annual report, on key human-capital initiatives and defined targets. This report is reviewed annually by the Board.